pegcrisantaspase
Recombinant proteinexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02257684)
Timeline
Indications
Studied for
Mechanism of action
- AsparagineDEGRADER
Asparagine degrader
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pegcrisantaspase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04666649 | Phase 1 | Mar 10, 2021 | University of Maryland |
| NCT04526795 | Phase 1 | Dec 31, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT02257684 | Phase 2 | Sep 1, 2014 | Jazz Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals | For profit | 1 | 1 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1